Buparlisib Hydrochloride is primarily used in the field of oncology as a targeted therapy for cancer treatment. It functions as a PI3K inhibitor, specifically targeting the PI3K pathway, which is often dysregulated in various cancers. This compound is particularly investigated in clinical trials for its potential to treat advanced or metastatic breast cancer, especially in cases where the cancer is hormone receptor-positive and HER2-negative. By inhibiting the PI3K pathway, it helps to slow down or stop the growth of cancer cells, offering a promising approach for patients who have not responded well to other treatments. Additionally, it is being explored for its efficacy in other types of cancers, including solid tumors and hematologic malignancies, providing a broader scope for its application in cancer therapy.